Navigation Links
NACCHO to Support Influenza Vaccination Efforts With Donation of Up to One Million Doses of FluMist(R)
Date:12/10/2008

WASHINGTON, Dec. 10 /PRNewswire/ -- The National Association of County and City Health Officials (NACCHO) today announced a donation of up to one million doses of FluMist(R) (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations.

NACCHO will make these donated doses of vaccine available to selected state and local health departments around the country starting this month. This joint NACCHO-MedImmune effort supports the goal of the Centers for Disease Control and Prevention (CDC) to broaden the influenza vaccination season into December and beyond. The CDC has launched National Influenza Vaccination Week (December 8-12) as a springboard to help educate the public on the importance of influenza vaccination throughout the winter. Vaccination rates typically decline after Thanksgiving, although the peak of influenza season usually occurs in February and March.

"NACCHO is pleased to partner with MedImmune to help increase the number of individuals vaccinated against influenza," said NACCHO President Gary Cox, J.D. "These doses of vaccine will go a long way to support a national objective of immunizing all persons who should receive flu vaccine, especially those who are least able to afford it."

Public health guidelines on annual influenza vaccination are broader than ever before. In February 2008, the CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand pediatric influenza vaccination recommendations to include school-age children ages 5 through 18 years. The expanded recommendations add 30 million children to the recommended pediatric population for annual influenza vaccination. In addition to influenza vaccination recommendations for specific populations (http://www.cdc.gov/flu), the CDC recommends that anyone who wants to reduce their chances of getting influenza or spreading it to others get vaccinated every year.

"We are proud to support NACCHO's objective of increasing flu vaccination rates across the country," stated Brian Rosen, MedImmune's senior director, government relations. "We at MedImmune take great pride in knowing this donation may help protect up to one million more eligible men, women, and children against influenza, and educate them about the importance of protecting themselves and their families against influenza."

About NACCHO

NACCHO (National Association of County and City Health Officials) is the national organization representing the nation's nearly 3,000 local health departments. These agencies work every day on the front lines to protect and promote the health of their communities. NACCHO develops resources and programs and promotes national policies that support effective local public health practice. For additional information about NACCHO, visit: http://www.naccho.org.

About FluMist

FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, available by calling 1-877-FLUMIST (1-877-358-6478) or visiting http://www.medimmune.com/pdf/products/flumist_pi.pdf for additional information.


'/>"/>
SOURCE NACCHO
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AT&T Supports the Smith Familys Learning For Life Program
2. American Lung Association Announces Support of Pickens Plan
3. Video: Childhood Influenza Immunization Coalition Supports Second Annual Childrens Flu Vaccination Day
4. Upsher-Smith Laboratories Launches Prenexa.com to Support Prenatal Nutrition and Health
5. Turn to Diabetic Care Services for Personalized Support and Hassle-Free Diabetes Supplies
6. Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus
7. Over 40 Hospitals Lend Support for Individual Insurance Market Reform
8. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
9. International study supports new standard of treatment for women with advanced ovarian cancer
10. MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care
11. Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
Breaking Medicine Technology: